BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sadeghi A, Ali Asgari A, Norouzi A, Kheiri Z, Anushirvani A, Montazeri M, Hosamirudsai H, Afhami S, Akbarpour E, Aliannejad R, Radmard AR, Davarpanah AH, Levi J, Wentzel H, Qavi A, Garratt A, Simmons B, Hill A, Merat S. Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial. J Antimicrob Chemother 2020;75:3379-85. [PMID: 32812039 DOI: 10.1093/jac/dkaa334] [Cited by in Crossref: 40] [Cited by in F6Publishing: 51] [Article Influence: 20.0] [Reference Citation Analysis]
Number Citing Articles
1 Chen C, Weng T, Chen Y, Kao JH, Chao C. Clinical efficacy of sofosbuvir/daclatasvir in patients with COVID-19: a systematic review and meta-analysis of randomized trials. Expert Review of Clinical Pharmacology. [DOI: 10.1080/17512433.2022.2103539] [Reference Citation Analysis]
2 Kalamatianos KG. In silico drug repurposing for coronavirus (COVID-19): screening known HCV drugs against the SARS-CoV-2 spike protein bound to angiotensin-converting enzyme 2 (ACE2) (6M0J). Mol Divers 2022. [PMID: 35739375 DOI: 10.1007/s11030-022-10469-7] [Reference Citation Analysis]
3 Zhang C. Fluorine in Medicinal Chemistry: In Perspective to COVID-19. ACS Omega 2022;7:18206-12. [PMID: 35663284 DOI: 10.1021/acsomega.2c01121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Medhat MA, El-kassas M, Karam-allah H, Al Shafie A, Abd-elsalam S, Moustafa E, Hassany SM, Salama M, Abd Elghafar MS, Sayed H, Badr M, Kamal DT, Shamseldeen A, Ossimi A, Moaz I, El-deen Esmael H, Ezz Eldin AM, Ezzat S, Abdelghaffar H, Abdelghaffar K. Sofosbuvir/Ledipasvir in Combination or Nitazoxanide Alone are Safe and Efficient Treatments for COVID-19 Infection: A Randomized Controlled Trial for Repurposing antivirals. Arab Journal of Gastroenterology 2022. [DOI: 10.1016/j.ajg.2022.04.005] [Reference Citation Analysis]
5 Ahmed FF, Reza MS, Sarker MS, Islam MS, Mosharaf MP, Hasan S, Mollah MNH. Identification of host transcriptome-guided repurposable drugs for SARS-CoV-1 infections and their validation with SARS-CoV-2 infections by using the integrated bioinformatics approaches. PLoS One 2022;17:e0266124. [PMID: 35390032 DOI: 10.1371/journal.pone.0266124] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Zhao L, Li S, Zhong W. Mechanism of Action of Small-Molecule Agents in Ongoing Clinical Trials for SARS-CoV-2: A Review. Front Pharmacol 2022;13:840639. [DOI: 10.3389/fphar.2022.840639] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
7 Wang X, Sacramento CQ, Jockusch S, Chaves OA, Tao C, Fintelman-Rodrigues N, Chien M, Temerozo JR, Li X, Kumar S, Xie W, Patel DJ, Meyer C, Garzia A, Tuschl T, Bozza PT, Russo JJ, Souza TML, Ju J. Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture. Commun Biol 2022;5:154. [PMID: 35194144 DOI: 10.1038/s42003-022-03101-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
8 Aslan AT, Akova M. Current status of therapeutic alternatives for COVID-19: A narrative review. Infez Med 2021;29:312-27. [PMID: 35146336 DOI: 10.53854/liim-2903-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
9 Yang H, Ding Y, Tang J, Guo F. Inferring human microbe–drug associations via multiple kernel fusion on graph neural network. Knowledge-Based Systems 2022;238:107888. [DOI: 10.1016/j.knosys.2021.107888] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Vegivinti CTR, Evanson KW, Lyons H, Akosman I, Barrett A, Hardy N, Kane B, Keesari PR, Pulakurthi YS, Sheffels E, Balasubramanian P, Chibbar R, Chittajallu S, Cowie K, Karon J, Siegel L, Tarchand R, Zinn C, Gupta N, Kallmes KM, Saravu K, Touchette J. Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials. BMC Infect Dis 2022;22:107. [PMID: 35100985 DOI: 10.1186/s12879-022-07068-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 11.0] [Reference Citation Analysis]
11 Mobarak S, Salasi M, Hormati A, Khodadadi J, Ziaee M, Abedi F, Ebrahimzadeh A, Azarkar Z, Mansour-Ghanaei F, Joukar F, Yeganeh S, Yaghubi Kalurazi T, Naghipour M, Mehrabi Z, Bahadori AR, Yaghoubi S, Moslemi R, Abbaspour Kasgari H, Fakheri H, Moghimi M, Shabani AM, Nekoukar Z, Babamahmoodi F, Davoudi Badabi AR, Davoodi L, Hassaniazad M, Barahimi E, Tousi A, Sadeghi A, Hosamirudsari H, Ali Asgari A, Abdollahi M, Anushiravani A, Shabani M, Shokouhi S, Khajavirad N, Salehi M, Dehghan Manshadi SA, Mousavi H, Zolfaghari F, Azimi E, Zeinali A, Akbarpour E, Merat D, Eslami G, Mousaviasl S, Sayar S, Radmanesh E, Ebrahimzadeh M, Arizavi Z, Jelvay S, Salmanzadeh S, Esmaeilian H, Mobarak M, Karimi J, Poormontaseri Z, Hasooni Bahrini N, Bonyadi A, Dehghani F, Mirzaei H, Noori Jangi M, Pourmasoomi H, Rezaie Keikhaie L, Afshari M, Nateghi Baygi A, Nateghi Baygi H, Levi J, McCann K, Wentzel H, Simmons B, Hill A, Merat S. Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER). J Antimicrob Chemother 2021:dkab433. [PMID: 34849957 DOI: 10.1093/jac/dkab433] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
12 Kow CS, Javed A, Ramachandram D, Hasan SS. Clinical outcomes of sofosbuvir-based antivirals in patients with COVID-19: a systematic review and meta-analysis of randomized trials. Expert Rev Anti Infect Ther 2021;:1-9. [PMID: 34719324 DOI: 10.1080/14787210.2022.2000861] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Asili P, Mirahmad M, Tabatabaei-Malazy O, Manayi A, Haghighat E, Mahdavi M, Larijani B. Characteristics of published/registered clinical trials on COVID-19 treatment: A systematic review. Daru 2021;29:449-67. [PMID: 34762250 DOI: 10.1007/s40199-021-00422-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Aherfi S, Pradines B, Devaux C, Honore S, Colson P, Scola B, Raoult D. Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV. Future Microbiol 2021;16:1341-70. [PMID: 34755538 DOI: 10.2217/fmb-2021-0019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
15 Akbari A, Razmi M, Sedaghat A, Alavi Dana SMM, Amiri M, Halvani AM, Yazdani S, Sahab-Negah S. Comparative effectiveness of pharmacological interventions on mortality and the average length of hospital stay of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. Expert Rev Anti Infect Ther 2021. [PMID: 34694949 DOI: 10.1080/14787210.2022.1997587] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Zhang C, Jin H, Wen YF, Yin G. Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. Front Public Health 2021;9:729559. [PMID: 34650951 DOI: 10.3389/fpubh.2021.729559] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
17 Sharma S, Singh A, Banerjee T. Antibacterial agents used in COVID-19: A systematic review and meta-analysis. Environmental Sustainability 2021;4:503-13. [DOI: 10.1007/s42398-021-00194-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
18 Okoli GN, Rabbani R, Al-Juboori A, Copstein L, Askin N, Abou-Setta AM. Antiviral drugs for coronavirus disease 2019 (COVID-19): a systematic review with network meta-analysis. Expert Rev Anti Infect Ther 2021;:1-12. [PMID: 34323632 DOI: 10.1080/14787210.2021.1961579] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
19 Abbass S, Kamal E, Salama M, Salman T, Sabry A, Abdel-Razek W, Helmy S, Abdelgwad A, Sakr N, Elgazzar M, Einar M, Farouk M, Saif M, Shehab I, El-Hosieny E, Mansour M, Mahdi D, Tharwa ES, Salah M, Elrouby O, Waked I. Efficacy and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with COVID-19: A randomized controlled trial. J Med Virol 2021. [PMID: 34379337 DOI: 10.1002/jmv.27264] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
20 Wang X, Sacramento CQ, Jockusch S, Chaves OA, Tao C, Fintelman-Rodrigues N, Chien M, Temerozo JR, Li X, Kumar S, Xie W, Patel DJ, Meyer C, Garzia A, Tuschl T, Bozza PT, Russo JJ, Souza TML, Ju J. Combination of Antiviral Drugs to Inhibit SARS-CoV-2 Polymerase and Exonuclease as Potential COVID-19 Therapeutics. bioRxiv 2021:2021. [PMID: 34312622 DOI: 10.1101/2021.07.21.453274] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Sayad B, Khodarahmi R, Najafi F, Miladi R, Mohseni Afshar Z, Mansouri F, Rahimi Z, Shirvani M, Salimi M, Vaziri S, Janbakhsh A, Khosravi Shadmani F, Bozorgomid A, Zamanian MH, Afsharian M. Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial. J Antimicrob Chemother 2021;76:2158-67. [PMID: 34037760 DOI: 10.1093/jac/dkab152] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
22 Honarmand K, Penn J, Agarwal A, Siemieniuk R, Brignardello-Petersen R, Bartoszko JJ, Zeraatkar D, Agoritsas T, Burns K, Fernando SM, Foroutan F, Ge L, Lamontagne F, Jimenez-Mora MA, Murthy S, Yepes-Nuñez JJ, Vandvik PO, Ye Z, Rochwerg B. Clinical trials in COVID-19 management & prevention: A meta-epidemiological study examining methodological quality. J Clin Epidemiol 2021;139:68-79. [PMID: 34274489 DOI: 10.1016/j.jclinepi.2021.07.002] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
23 Hassanzadeganroudsari M, Ahmadi AH, Rashidi N, Hossain MK, Habib A, Apostolopoulos V. Computational Chemistry to Repurposing Drugs for the Control of COVID-19. Biologics 2021;1:111-28. [DOI: 10.3390/biologics1020007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 El-Bendary M, Abd-Elsalam S, Elbaz T, El-Akel W, Cordie A, Elhadidy T, Elalfy H, Farid K, Elegezy M, El-Badrawy A, Neamatallah M, Abd Elghafar M, Salama M, AbdAllah M, Essam M, El-Shazly M, Esmat G. Efficacy of combined Sofosbuvir and Daclatasvir in the treatment of COVID-19 patients with pneumonia: a multicenter Egyptian study. Expert Rev Anti Infect Ther 2021;:1-5. [PMID: 34225541 DOI: 10.1080/14787210.2021.1950532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
25 Wang D, Chen L, Wang L, Hua F, Li J, Li Y, Zhang Y, Fan H, Li W, Clarke M. Abstracts for reports of randomised trials of COVID-19 interventions had low quality and high spin. J Clin Epidemiol 2021:S0895-4356(21)00205-5. [PMID: 34224834 DOI: 10.1016/j.jclinepi.2021.06.027] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
26 Lai CC, Chao CM, Hsueh PR. Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials. J Microbiol Immunol Infect 2021:S1684-1182(21)00135-3. [PMID: 34253490 DOI: 10.1016/j.jmii.2021.05.011] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
27 Zein AFMZ, Sulistiyana CS, Raffaello WM, Wibowo A, Pranata R. Sofosbuvir with daclatasvir and the outcomes of patients with COVID-19: a systematic review and meta-analysis with GRADE assessment. Postgrad Med J 2021:postgradmedj-2021-140287. [PMID: 34103373 DOI: 10.1136/postgradmedj-2021-140287] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
28 Bassetti M, Corcione S, Dettori S, Lombardi A, Lupia T, Vena A, De Rosa FG, Gori A, Giacobbe DR. Antiviral treatment selection for SARS-CoV-2 pneumonia. Expert Rev Respir Med 2021;15:985-92. [PMID: 33962524 DOI: 10.1080/17476348.2021.1927719] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Scavone C, Mascolo A, Rafaniello C, Sportiello L, Trama U, Zoccoli A, Bernardi FF, Racagni G, Berrino L, Castaldo G, Coscioni E, Rossi F, Capuano A. Therapeutic strategies to fight COVID-19: Which is the status artis? Br J Pharmacol 2021. [PMID: 33960398 DOI: 10.1111/bph.15452] [Cited by in Crossref: 3] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
30 Qiu R, Li J, Xiao Y, Gao Z, Weng Y, Zhang Q, Wang C, Gong H, Li W. The therapeutic effect and safety of the drugs for COVID-19: A systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e25532. [PMID: 33879694 DOI: 10.1097/MD.0000000000025532] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Park JJH, Mogg R, Smith GE, Nakimuli-Mpungu E, Jehan F, Rayner CR, Condo J, Decloedt EH, Nachega JB, Reis G, Mills EJ. How COVID-19 has fundamentally changed clinical research in global health. Lancet Glob Health 2021;9:e711-20. [PMID: 33865476 DOI: 10.1016/S2214-109X(20)30542-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
32 Spera AM. Are nucleotide inhibitors, already used for treating hepatitis C virus infection, a potential option for the treatment of COVID-19 compared with standard of care? A literature review. World J Virol 2021; 10(2): 53-61 [PMID: 33816150 DOI: 10.5501/wjv.v10.i2.53] [Reference Citation Analysis]
33 Khan S, Attar F, Bloukh SH, Sharifi M, Nabi F, Bai Q, Khan RH, Falahati M. A review on the interaction of nucleoside analogues with SARS-CoV-2 RNA dependent RNA polymerase. Int J Biol Macromol 2021;181:605-11. [PMID: 33766591 DOI: 10.1016/j.ijbiomac.2021.03.112] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
34 Zhao MZ, Zhao C, Tu SS, Wei XX, Shang HC. Evaluating the methodology of studies conducted during the global COVID-19 pandemic: A systematic review of randomized controlled trials. J Integr Med 2021;19:317-26. [PMID: 33789839 DOI: 10.1016/j.joim.2021.03.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
35 Yang Y, Cui X, Wei H, Guo C, Zhang Y. Potential Anti-Coronavirus Agents and the Pharmacologic Mechanisms. Drug Des Devel Ther 2021;15:1213-23. [PMID: 33762818 DOI: 10.2147/DDDT.S293216] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
36 Welte T, Ambrose LJ, Sibbring GC, Sheikh S, Müllerová H, Sabir I. Current evidence for COVID-19 therapies: a systematic literature review. Eur Respir Rev 2021;30:200384. [PMID: 33731328 DOI: 10.1183/16000617.0384-2020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
37 Juul S, Nielsen EE, Feinberg J, Siddiqui F, Jørgensen CK, Barot E, Holgersson J, Nielsen N, Bentzer P, Veroniki AA, Thabane L, Bu F, Klingenberg S, Gluud C, Jakobsen JC. Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). PLoS One 2021;16:e0248132. [PMID: 33705495 DOI: 10.1371/journal.pone.0248132] [Cited by in Crossref: 5] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
38 Khani E, Khiali S, Entezari-Maleki T. Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review. J Clin Pharmacol 2021;61:429-60. [PMID: 33511638 DOI: 10.1002/jcph.1822] [Cited by in Crossref: 6] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
39 Vicenti I, Zazzi M, Saladini F. SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19. Expert Opin Ther Pat 2021;31:325-37. [PMID: 33475441 DOI: 10.1080/13543776.2021.1880568] [Cited by in Crossref: 10] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
40 Españo E, Kim D, Kim J, Park SK, Kim JK. COVID-19 Antiviral and Treatment Candidates: Current Status. Immune Netw 2021;21:e7. [PMID: 33728100 DOI: 10.4110/in.2021.21.e7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
41 Borbone N, Piccialli G, Roviello GN, Oliviero G. Nucleoside Analogs and Nucleoside Precursors as Drugs in the Fight against SARS-CoV-2 and Other Coronaviruses. Molecules 2021;26:986. [PMID: 33668428 DOI: 10.3390/molecules26040986] [Cited by in F6Publishing: 34] [Reference Citation Analysis]
42 Roozbeh F, Saeedi M, Alizadeh-Navaei R, Hedayatizadeh-Omran A, Merat S, Wentzel H, Levi J, Hill A, Shamshirian A. Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial. J Antimicrob Chemother 2021;76:753-7. [PMID: 33338232 DOI: 10.1093/jac/dkaa501] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 27.0] [Reference Citation Analysis]
43 Simmons B, Wentzel H, Mobarak S, Eslami G, Sadeghi A, Ali Asgari A, Abbaspour Kasgari H, Tirgar Fakheri H, Merat S, Hill A. Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis. J Antimicrob Chemother. 2021;76:286-291. [PMID: 33063117 DOI: 10.1093/jac/dkaa418] [Cited by in Crossref: 8] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
44 Han YJ, Lee KH, Yoon S, Nam SW, Ryu S, Seong D, Kim JS, Lee JY, Yang JW, Lee J, Koyanagi A, Hong SH, Dragioti E, Radua J, Smith L, Oh H, Ghayda RA, Kronbichler A, Effenberger M, Kresse D, Denicolò S, Kang W, Jacob L, Shin H, Shin JI. Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of in vitro, in vivo, and clinical trials. Theranostics 2021;11:1207-31. [PMID: 33391531 DOI: 10.7150/thno.48342] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
45 Tam NM, Pham MQ, Ha NX, Nam PC, Phung HTT. Computational estimation of potential inhibitors from known drugs against the main protease of SARS-CoV-2. RSC Adv 2021;11:17478-86. [DOI: 10.1039/d1ra02529e] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
46 Zhaori G, Lu L, Liu C, Guo Y. Progresses in clinical studies on antiviral therapies for COVID-19-Experience and lessons in design of clinical trials. Pediatr Investig 2020;4:263-74. [PMID: 33376954 DOI: 10.1002/ped4.12227] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
47 Chan HT, Chao CM, Lai CC. Sofosbuvir/daclatasvir in the treatment of COVID-19 infection: A meta-analysis. J Infect 2021;82:e34-5. [PMID: 33373651 DOI: 10.1016/j.jinf.2020.12.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
48 Hanafy AS, Abd-Elsalam S. Challenges in COVID-19 drug treatment in patients with advanced liver diseases: A hepatology perspective. World J Gastroenterol 2020; 26(46): 7272-7286 [PMID: 33362383 DOI: 10.3748/wjg.v26.i46.7272] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
49 Khalili H, Nourian A, Ahmadinejad Z, Emadi Kouchak H, Jafari S, Dehghan Manshadi SA, Rasolinejad M, Kebriaeezadeh A. Efficacy and safety of sofosbuvir/ ledipasvir in treatment of patients with COVID-19; A randomized clinical trial. Acta Biomed 2020;91:e2020102. [PMID: 33525212 DOI: 10.23750/abm.v91i4.10877] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
50 Ju J, Li X, Kumar S, Jockusch S, Chien M, Tao C, Morozova I, Kalachikov S, Kirchdoerfer RN, Russo JJ. Nucleotide analogues as inhibitors of SARS-CoV Polymerase. Pharmacol Res Perspect 2020;8:e00674. [PMID: 33124786 DOI: 10.1002/prp2.674] [Cited by in Crossref: 10] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
51 Ortega JT, Zambrano JL, Jastrzebska B, Liprandi F, Rangel HR, Pujol FH. Understanding Severe Acute Respiratory Syndrome Coronavirus 2 Replication to Design Efficient Drug Combination Therapies. Intervirology 2020;63:2-9. [PMID: 33099545 DOI: 10.1159/000512141] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
52 Jockusch S, Tao C, Li X, Chien M, Kumar S, Morozova I, Kalachikov S, Russo JJ, Ju J. Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir. Sci Rep. 2020;10:16577. [PMID: 33024223 DOI: 10.1038/s41598-020-73641-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 38] [Article Influence: 8.0] [Reference Citation Analysis]